Eva MD - IO Biotech Chief Officer
| IOBT Stock | USD 0.92 0.04 4.55% |
Insider
Eva MD is Chief Officer of IO Biotech
| Age | 60 |
| Phone | 45 70 70 29 80 |
| Web | https://www.iobiotech.com |
IO Biotech Management Efficiency
The company has return on total asset (ROA) of (0.4591) % which means that it has lost $0.4591 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.785) %, meaning that it created substantial loss on money invested by shareholders. IO Biotech's management efficiency ratios could be used to measure how well IO Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jacquelyn JD | Cullinan Oncology LLC | 47 | |
| Jason CPA | MediciNova | 47 | |
| Maria Mancini | Champions Oncology | N/A | |
| MBA MD | Cullinan Oncology LLC | 51 | |
| Ellen MBA | Werewolf Therapeutics | 48 | |
| David MBA | Champions Oncology | 56 | |
| Lina Gugucheva | NewAmsterdam Pharma | 37 | |
| Chandra Lovejoy | Erasca Inc | 53 | |
| Jason Cavalier | Lyra Therapeutics | 51 | |
| Casi DeYoung | Shattuck Labs | 54 | |
| Osvaldo Flores | Century Therapeutics | 61 | |
| Dawn Kalmar | Stoke Therapeutics | 47 | |
| Chulani Karunatilake | Werewolf Therapeutics | 65 | |
| Anne Lesage | Pharvaris BV | 64 | |
| Joo MD | Design Therapeutics | 61 | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Aseem Ansari | Design Therapeutics | N/A | |
| Ajim CFA | Monte Rosa Therapeutics | 47 | |
| JeanPaul MD | Inventiva Sa | N/A | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| John Castle | Monte Rosa Therapeutics | 54 | |
Management Performance
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.46 |
IO Biotech Leadership Team
Elected by the shareholders, the IO Biotech's board of directors comprises two types of representatives: IO Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IOBT. The board's role is to monitor IO Biotech's management team and ensure that shareholders' interests are well served. IO Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IO Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MaiBritt Zocca, President, Founder | ||
| Qasim MD, Chief Officer | ||
| Faical Miyara, Chief Officer | ||
| Brian CPA, Chief Officer | ||
| Amy Sullivan, Chief Officer | ||
| Anders Ljungqvist, Founder | ||
| Brian Burkavage, Chief Officer | ||
| Pr Andersen, Founder Advisor | ||
| Eva MD, Chief Officer | ||
| Pr MD, CoFounder Advisor | ||
| Pr Straten, Founder | ||
| Devin Smith, General Secretary | ||
| Daniel Mannix, Senior Affairs | ||
| Eric MBA, Chief Officer | ||
| Muhammad AlHajj, Chief Officer | ||
| Mikkel Dybkjr, VP Fin | ||
| Amy MBA, Chief Officer | ||
| Devin JD, General Secretary | ||
| Marjan PharmD, Senior Lead | ||
| Diane McDowell, Senior Affairs |
IOBT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IO Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | (20.7 M) | ||||
| Shares Outstanding | 65.88 M | ||||
| Shares Owned By Insiders | 0.29 % | ||||
| Shares Owned By Institutions | 67.37 % | ||||
| Number Of Shares Shorted | 24.27 K | ||||
| Price To Book | 0.79 X | ||||
| EBITDA | (91.23 M) | ||||
| Net Income | (86.08 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for IOBT Stock Analysis
When running IO Biotech's price analysis, check to measure IO Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IO Biotech is operating at the current time. Most of IO Biotech's value examination focuses on studying past and present price action to predict the probability of IO Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IO Biotech's price. Additionally, you may evaluate how the addition of IO Biotech to your portfolios can decrease your overall portfolio volatility.